Building the Next Generation

Antibody therapies are ripe for innovation and DotBio aims to be a leader in next-generation immuno-oncology.

Exploring several innovative technologies and our cutting edge expertise in protein science we aim to transform multi-specific antibody therapies in the oncology area.

As an Asia-born pharmaceutical company, our strategy is to partner globally and to rapidly establish a clinical pipeline based on our unique DotBody technology.


The Team


Dr. Ignacio Asial


Expertise: Protein and antibody engineering, design and conception of the Dotbody technology.

Dr. Ignacio Asial holds a M.Sc. in Biological Engineering from Ecole d’Ingénieurs Polytech Marseille (France), a M.Sc. in Bioinformatics, Structural Biology and Genomics from Aix-Marseille University (France), and a Ph.D. in Biological Sciences from Nanyang Technological University (Singapore). He has worked in both private (Genentech USA, Ambrilia Biopharma France) and public sectors (CNRS France, NTU Singapore, UCSF USA).

Role: Leads research and development, business development.


Prof. Pär Nordlund


Expertise: Structural biology, drug development, technology innovation, serial entrepreneur.

Prof. Nordlund holds a PhD from Swedish University of Agriculture and a MSc in Physics Engineering from Uppsala University. He is a Professor at Karolinska Institutet (Sweden) and Nanyang Technological University (Singapore), and a principal investigator at Agency for Science, Technology and Research (Singapore). He has a prolific scientific career spanning more than 25 years, regularly publishing in top-tier scientific journals.

He is also a member of the Nobel Prize Committee, the Nobel Assembly and the Swedish Academy of Science.

Prof. Nordlund has over a decade of entrepreneurial expertise, having founded several successful Swedish biotechnology companies: Sprint Biosciences (2009), Pelago Biosciences (2012) and DotBio (2018).

Role: Scientific advisor, scientific outreach and collaborations, international networking.

Kelly Profile picture.jpg

Dr. Kelly Hew


Expertise: structural biology and protein chemistry, biophysical and cell-based antibody validation.

Dr. Kelly Hew holds a B.Sc. and a Ph.D. in Biological Sciences from Nanyang Technological University (Singapore).

Dr. Hew has a strong background in protein production, protein engineering, structural biology and protein biophysics. She is in charge of the generation of DotBody lead candidates at our protein sciences team.

Role: Leads operations and protein sciences team.

Board of Directors


Dr. Ignacio Asial

Founder and Chief Executive Officer at DotBio.


Prof. Pär Nordlund

Founder and Scientific Advisor at DotBio.

Professor at Karolinska Institute (Sweden). Visiting Professor at Nanyang Technological University (Singapore). Member of the Nobel Prize Assembly (Sweden).


Dr. Carl Firth

Founder and Chief Executive Officer at ASLAN Pharmaceuticals (Singapore).

Previous positions held: Head of Asia Healthcare at Bank of America Merrill Lynch; Regional Business Development Director (Asia Pacific) at AstraZeneca; Director of New Product Development (China) at AstraZeneca.

Dr. Firth is an Adjunct Professor at Duke-NUS Medical School. He has a PhD in Molecular Biology from Cambridge University (Trinity College), an Executive MBA from London Business School; and a BA in Molecular Biology from Cambridge University.


Mr. Kingsley Leung

Chairman at Uni-Bio Science (Hong Kong).

Previous positions held: Business Development Manager at Uni-Bio Science, Business Development Manager of ASLAN Pharmaceuticals. 

Mr. Leung holds a BSc in Biochemistry from Imperial College London (UK) and an MSc in Pharmacology from the University of Oxford (UK). In addition, he holds a Professional Diploma in Corporate Governance & Directorship from the Hong Kong Institute of Directors.

External advisors


Dr. Bertil Lindmark

Scientific Advisor

Chief Medical Officer at ASLAN Pharmaceuticals (Singapore).

Previous positions held:  Executive Director of Research and Development and a Member of the Board of Directors at Almirall SA; Vice President and Head of Clinical Development at AstraZeneca; Vice President of Respiratory and Inflammation Clinical Development at AstraZeneca.

Dr. Lindmark holds a MD and PhD in Molecular Epidemiology from the University of Lund (Sweden), and specialist qualifications in Internal Medicine and Gastroenterology.


Dr. Dineli Wickramasinghe

Scientific Advisor

Founding Partner at DWSO Biopharma Consulting LLC (San Francisco).

Previous positions held:  Chief Scientific Officer at Affinita Biotech; Executive Director of Oncology at Amgen; Senior Scientist at Genentech.

Dr. Wickramasinghe holds a B.A. from Mount Holyoke College (USA) and a PhD from Tuft University (USA). She also obtained a postdoctoral fellowship in molecular genetics at the National Cancer Institute (USA).


Founder at The Thought Disruptor.

Previous positions held: CEO at several biotechnology firms (Cambridge Biotechnology Ltd, DanioLabs, Novacta Ltd, Silence Therapeutics); Board member and/or Chairman (Midian Clinical, Virobiotech, Celentyx, Vantia Therapeutics, Plastid AS, ThioLogics, Microvisk); Global Head of Clinical Operations at Roche.

Dr. Sedgwick holds a PhD FRCPath in Pathology/Experimental Pathology from St. Bartholomews Hospital Medical School (UK).


Strategy Advisor